• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jennifer R. Brown, MD, PhD


  • Wang L, Shalek AK, Lawrence M, Ding R, Gaublomme JT, Pochet N, Stojanov P, Sougnez C, Shukla SA, Stevenson KE, Zhang W, Wong J, Sievers QL, MacDonald BT, Vartanov AR, Goldstein NR, Neuberg D, He X, Lander E, Hacohen N, Regev A, Getz G, Brown JR, Park H, Wu CJ.Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.Blood. 2014 Aug 14(7):1089-98.
  • Sobecks RM, Leis JF, Gale RP, Ahn KW, Zhu X, Sabloff M, de Lima M, Brown JR, Inamoto Y, Hale GA, Aljurf MD, Kamble RT, Hsu JW, Pavletic SZ, Wirk B, Seftel MD, Lewis ID, Alyea EP, Cortes J, Kalaycio ME, Maziarz RT, Saber W.Outcomes of Human Leukocyte Antigen-Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens.Biol Blood Marrow Transplant. 2014 May 28.
  • Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P, .Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia.N Engl J Med. 2014 May 31.
  • Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR.Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.Blood. 2014 May 29(22):3390-7.
  • James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ.Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium.J Clin Oncol. 2014 May 27.
  • Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC.Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.Blood. 2014 May 27.
  • Brown JR, Porter DL, O'Brien SM.Novel treatments for chronic lymphocytic leukemia and moving forward.Am Soc Clin Oncol Educ Book. 2014;34:e317-25.
  • Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, Gray NS.Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.ACS Chem Biol. 2014 May 16(5):1086-91.
  • Houldsworth J, Guttapalli A, Thodima V, Yan XJ, Mendiratta G, Zielonka T, Nanjangud G, Chen W, Patil S, Mato A, Brown JR, Rai K, Chiorazzi N, Chaganti RS.Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia.Leuk Lymphoma. 2014 Apr;55(4):920-8.
  • Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, Danilov AV.The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells.Clin Cancer Res. 2014 Mar 15;20(6):1576-89.
  • Velez NF, Karia PS, Vartanov AR, Davids MS, Brown JR, Schmults CD.Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia.JAMA Dermatol. 2014 Mar;150(3):280-7.
  • Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND.Results of a phase I study of idelalisib, a PI3Kδ inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL).Blood. 2014 Mar 10.
  • Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE.Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Blood. 2014 Mar 10.
  • Sabloff M, Sobecks RM, Ahn KW, Zhu X, de Lima M, Brown JR, Inamoto Y, Holland HK, Aljurf MD, Laughlin MJ, Kamble RT, Hsu JW, Wirk BM, Seftel M, Lewis ID, Arora M, Alyea EP, Kalaycio ME, Cortes J, Maziarz RT, Gale RP, Saber W.Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?.Biol Blood Marrow Transplant. 2014 Mar;20(3):421-4.
  • Brown JR.B-cell receptor inhibitors in chronic lymphocytic leukemia.Clin Adv Hematol Oncol. 2013 Jun;11(6):362-4.
  • Brown JR.A new era of treatment for chronic lymphocytic leukaemia?.Lancet Oncol. 2014 Jan;15(1):3-5.
  • Pyo J, Won Kim K, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD.End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis.Clin Cancer Res. 2013 Dec 1;19(23):6566-77.
  • Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS.Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.British Journal of Haematology. 2013 Oct;163(1):123-6.
  • Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ.Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.J Clin Invest. 2013 Sep 3;123(9):3756-65.
  • Brown JR.Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future.Ther Adv Hematol. 2013 Aug;4(4):298-308.
  • Brown JR.Ibrutinib in CLL and B Cell Malignancies.Leuk Lymphoma. 2013 May 9.
  • Brown JR, Messmer BT, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, Lacasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS.A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia / small lymphocytic lymphoma.Haematologica. 2013 May 3.
  • Davids MS, Letai A, Brown JR.Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition.Leuk Lymphoma. 2013 Apr 25.
  • Brown JR.Preface.Hematol Oncol Clin North Am. 2013 Apr;27(2):xiii-xiv.
  • Davids MS, Brown JR.Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.Hematol Oncol Clin North Am. 2013 Apr;27(2):329-39.
  • Improgo MR, Brown JR.Genomic approaches to chronic lymphocytic leukemia.Hematol Oncol Clin North Am. 2013 Apr;27(2):157-71.
  • Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, Varettoni M, Varettoni M, Brown JR, Tai YT, Anderson KC, Munshi NC, Patterson CJ, Manning RJ, Tripsas CK, Lindeman NI, Treon SP.MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.Blood. 2013 Mar 14;121(11):2051-8.
  • Brown JR.Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.Curr Hematol Malig Rep. 2013 Mar;8(1):1-6.
  • Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ.Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.Cell. 2013 Feb 14;152(4):714-26.
  • Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB.Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.British Journal of Haematology. 2013 Mar;160(5):608-17.
  • Abramson JS, Takvorian RW, Fisher DC, Feng Y, Jacobsen ED, Brown JR, Barnes JA, Neuberg DS, Hochberg EP.Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study.Leuk Lymphoma. 2013 Jan 30.
  • Shalek AK, Gaublomme JT, Wang L, Yosef N, Chevrier N, Andersen MS, Robinson JT, Pochet N, Neuberg D, Gertner RS, Amit I, Brown JR, Hacohen N, Regev A, Wu CJ, Park H.Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia.Nano Lett. 2012 Dec 12;12(12):6498-504.
  • Brown JR.Gastric MALT Resistant to H Pylori Eradication: What's the Best Option?.Leuk Lymphoma. 2012 Nov 6.
  • Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A.Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.Blood. 2012 Oct 25;120(17):3501-9.
  • Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM.LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.Blood. 2012 Aug 23;120(8):1678-86.
  • Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM.BCL2 suppresses PARP1 function and nonapoptotic cell death.Cancer Res. 2012 Aug 15;72(16):4193-203.
  • Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, Wang YE, Dal Cin P, Fernandes SM, Thompson C, Macconaill L, Wu CJ, Van de Peer Y, Correll M, Regev A, Neuberg D, Freedman AS.Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.Clin Cancer Res. 2012 Jul 15;18(14):3791-802.
  • Brown JR.Insulin Receptor Activation in Deletion 11q Chronic Lymphocytic Leukemia.Clin Cancer Res. 2011 Mar 22.
  • Friese CR, Earle CC, Magazu LS, Brown JR, Neville BA, Hevelone ND, Richardson LC, Abel GA.Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia.Cancer. 2011 Apr 1;117(7):1470-7.
  • Li S, Moffett HF, Lu J, Werner L, Zhang H, Ritz J, Neuberg D, Wucherpfennig KW, Brown JR, Novina CD.MicroRNA Expression Profiling Identifies Activated B Cell Status in Chronic Lymphocytic Leukemia Cells.PLoS ONE. 2011;6(3):e16956.
  • Hartlerode A, Odate S, Shim I, Brown J, Scully R.Cell Cycle-Dependent Induction of Homologous Recombination by a Tightly Regulated I-SceI Fusion Protein.PLoS ONE. 2011;6(3):e16501.
  • Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA, Brown JR, Qin X.Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis.Cancer Res. 2011 Mar 15;71(6):2298-307.
  • Amrein PC, Attar EC, Takvorian RW, Hochberg EP, Ballen KK, Leahy KM, Fisher DE, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg DS, Brown JR.Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.Clin Cancer Res. 2011 Mar 14.
  • Abou-Nassar K, Brown JR.Novel agents for the treatment of chronic lymphocytic leukemia.Clin Adv Hematol Oncol. 2010 Dec;8(12):886-95. Review.
  • Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM, .Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia.Cancer. 2011 Jan 1;117(1):116-24.
  • Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell' Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW.Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium.Cancer Genet Cytogenet. 2010 Dec;203(2):141-8.
  • Heerema NA, Byrd JC, Dal Cin PS, Dell' Aquila ML, Koduru PR, Aviram A, Smoley SA, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps TJ, Kay NE, Van Dyke DL, .Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study.Cancer Genet Cytogenet. 2010 Dec;203(2):134-40.
  • Danilov AV, Danilova OV, Brown JR, Rabinowitz A, Klein AK, Huber BT.Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia.Exp Hematol. 2010 Dec;38(12):1167-77.
  • Brown JR, Abramson J, Hochberg E, Mikler E, Dalton V, Werner L, Reynolds H, Thompson C, McDonough SM, Kuang Y, Ritz J, Neuberg D, Freedman AS.A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.Leukemia. 2010 Nov;24(11):1972-5.
  • Friese CR, Earle CC, Magazu LS, Brown JR, Neville BA, Hevelone ND, Richardson LC, Abel GA.Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia.Cancer. 2010 Nov 8.
  • Wierda WG, Chiorazzi N, Dearden C, Brown JR, Montserrat E, Shpall E, Stilgenbauer S, Muneer S, Grever M.Chronic lymphocytic leukemia: new concepts for future therapy.Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):369-78. Review.
  • Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR.Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization.British Journal of Haematology. 2010 Nov;151(4):336-45.
  • Brown JR.Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?.Leuk Lymphoma. 2010 Aug;51(8):1382-5.
  • Brown JR, Callaghan PT.Measurement of vorticity diffusion by NMR microscopy.J Magn Reson. 2010 May;204(1):21-5.
  • Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM.Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7.
  • Brown JR,Friedberg JW,Feng Y,Scofield S,Phillips K,Dal Cin P,Joyce R,Takvorian RW,Fisher DC,Fisher RI,Liesveld J,Marquis D,Neuberg D,Freedman AS.A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.British Journal of Haematology. 2009 Jun;145(6):741-8.
  • Brown JR, Freedman AS.ASCT in follicular lymphoma.Nat Rev Clin Oncol. 2009 Jul;6(7):380-2.
  • Armand P,Gannamaneni S,Kim HT,Cutler CS,Ho VT,Koreth J,Alyea EP,LaCasce AS,Jacobsen ED,Fisher DC,Brown JR,Canellos GP,Freedman AS,Soiffer RJ,Antin JH.Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.J Clin Oncol. 2008 Dec 10;26(35):5767-74.
  • Brown JR, Levine RL, Thompson C, Basile G, Gilliland DG, Freedman AS.Systematic genomic screen for tyrosine kinase mutations in CLL.Leukemia. 2008 Oct;22(10):1966-9.
  • Brown JR,Neuberg D,Phillips K,Reynolds H,Silverstein J,Clark JC,Ash M,Thompson C,Fisher DC,Jacobsen E,LaCasce AS,Freedman AS.Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders.British Journal of Haematology. 2008 Nov;143(3):361-8.
  • Rassenti LZ,Jain S,Keating MJ,Wierda WG,Grever MR,Byrd JC,Kay NE,Brown JR,Gribben JG,Neuberg DS,He F,Greaves AW,Rai KR,Kipps TJ.Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.Blood. 2008 Sep 1;112(5):1923-30.
  • Ruddy KJ,Wu D,Brown JR.Pseudohyperkalemia in chronic lymphocytic leukemia.J Clin Oncol. 2008 Jun 1;26(16):2781-2.
  • Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP.Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25.
  • Ghia EM, Jain S, Widhopf GF 2nd, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ.Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.Blood. 2008 May 15;111(10):5101-8.
  • Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ.Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.J Clin Oncol. 2008 Jan 10;26(2):196-203.
  • Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A, Gradishar WJ.A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.Cancer Invest. 2007 Dec;25(8):733-7.
  • Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS.Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.Biol Blood Marrow Transplant. 2007 Sep;13(9):1057-65.
  • Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, Corbley MJ, Parr M, Ho M, Pastan I, Machuzak M, Benedict W, Zhang XQ, Lord EM, Litzky LA, Heitjan DF, June CH, Kaiser LR, Vonderheide RH, Albelda SM, Kanther M.A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4456-66.
  • Chen YB, Yu H, Gillani A, Brown JR.AIDS-associated plasmablastic lymphoma presenting at the insertion site of a peritoneal dialysis catheter.J Clin Oncol. 2007 Jul 20;25(21):3176-8.
  • Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A.Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.J Clin Invest. 2007 Jan;117(1):112-21.
  • Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP.Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64.
  • Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS.Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.J Clin Oncol. 2005 Apr 1;23(10):2208-14.
  • Brown JR, Skarin AT.Clinical mimics of lymphoma.Oncologist. 2004;9(4):406-16.
  • Brown JR, Weng AP, Freedman AS.Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature.Am J Clin Pathol. 2004 May;121(5):701-8.
  • Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC, Gribben JG, Kim H, Nadler LM, Freedman AS.Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma.Leuk Lymphoma. 2004 Feb;45(2):315-20.
  • Brown JR, Demetri GD.Challenges in the development of platelet growth factors: low expectations for low counts.Curr Hematol Rep. 2002 Nov;1(2):110-8.
  • Brown JR, Kuter DJ.The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.Thromb Haemost. 2001 Jun;85(6):979-85.
  • Brown JR, Nigh E, Lee RJ, Ye H, Thompson MA, Saudou F, Pestell RG, Greenberg ME.Fos family members induce cell cycle entry by activating cyclin D1.Mol Cell Biol. 1998 Sep;18(9):5609-19.
  • Brown JR, Ye H, Bronson RT, Dikkes P, Greenberg ME.A defect in nurturing in mice lacking the immediate early gene fosB.Cell. 1996 Jul 26;86(2):297-309.